<DOC>
	<DOCNO>NCT01991210</DOCNO>
	<brief_summary>This randomize , multicenter , open-label study evaluate safety efficacy DNIB0600A ( RO5541081 ) comparison PLD participant PROC , primary peritoneal cancer fallopian tube cancer . Participants randomize receive either DNIB0600A 2.4 milligram per kilogram ( mg/kg ) intravenously ( IV ) every 3 week PLD 40 milligram per meter-squared ( mg/m^2 ) IV every 4 week .</brief_summary>
	<brief_title>A Study DNIB0600A Comparison With Pegylated Liposomal Doxorubicin ( PLD ) Participants With Platinum-Resistant Ovarian Cancer ( PROC )</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Histologically document epithelial ovarian cancer , primary peritoneal cancer , fallopian tube cancer Advanced epithelial ovarian , primary peritoneal , fallopian tube cancer progress relapse within 6 month recent treatment platinumcontaining chemotherapy regimen PLD appropriate therapy No 1 prior cytotoxic chemotherapy regimens treatment PROC 2 total regimen ( define therapy [ approve investigational ] intent treat ovarian cancer ) Adequate hematologic , renal liver function Willing able perform patientreported outcome ( PRO ) survey ( include possibility use electronic PRO device ) For woman childbearing potential , agreement use 1 highly effective form contraception define protocol course study treatment 6 month last dose study treatment Primary platinumrefractory disease define disease progression within 2 month firstline , platinumcontaining chemotherapy regimen Antitumor therapy , include chemotherapy , biologic , experimental , hormonal therapy , within 4 week prior Day 1 Palliative radiation within 2 week prior Day 1 Prior anthracycline therapy , include prior treatment PLD ( example , Doxil® , Caelyx® , Lipodox® ) setting ( example , combination carboplatin single agent ) Prior treatment NaPi2b SCL34A2 target therapy Major surgical procedure within 4 week prior Day 1 Current Grade great ( &gt; ) 1 toxicity ( except alopecia anorexia ) prior therapy Grade &gt; 1 neuropathy cause Left ventricular ejection fraction define multigated acquisition ( MUGA ) /echocardiogram institutional low limit normal Evidence significant , uncontrolled , concomitant disease could affect compliance protocol interpretation result , include significant cardiovascular disease significant pulmonary disease Known active infection , major episode infection require treatment IV antibiotic hospitalization ( within 4 week prior Cycle 1 , Day 1 ) Clinically significant history liver disease , include viral hepatitis , current alcohol abuse , cirrhosis Presence positive test result hepatitis B hepatitis C detail protocol Known history HIV seropositive status Other malignancy within last 5 year , except adequately treat carcinoma situ cervix , squamous carcinoma skin , adequately control limited basal cell skin cancer , synchronous primary endometrial cancer prior primary endometrial cancer Untreated active central nervous system metastasis ( progress require anticonvulsant corticosteroid symptomatic control ) Pregnancy breastfeed Known history NaPi2b deficiency ( example , congenital alveolar microlithiasis testicular microlithiasis ) History severe allergic anaphylactic reaction monoclonal antibody therapy ( recombinant antibodyrelated fusion protein ) Metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may render participant high risk treatment complication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>